Pulmonary arterial hypertension, which is characterized by vascular proliferation and
remodeling of small pulmonary vessels, leads to a progressive increase in pulmonary …

toward lung regions with better ventilation and a higher intraalveolar partial pressure of
oxygen. Inhaled NO enhances this mechanism by increasing blood flow to well-ventilated …

Level of Evidence A Data derived from multiple randomised clinical trials or meta-analyses
Level of Evidence B Data derived from a single randomised clinical trial or large non …

Objectives: We sought to compare the short-termimpact of three different phosphodiesterase-
5 (PDE5) inhibitors on pulmonary and systemic hemodynamics and gas exchange …

Background: Alveolar hypoxia causes pulmonary hypertension and enhanced right
ventricular afterload, which may impair exercise tolerance. The phosphodiesterase-5 …

Sildenafil, a phosphodiesterase 5 inhibitor, is currently under investigation for therapy of
pulmonary hypertension. This study was designed to investigate chronic effects of sildenafil …

Pulmonary hypertension (PH) can develop in lung fibrosis, and contributes to increased
morbidity and mortality. Noninvasive parameters in the evaluation of PH in lung disease …

It is well-recognized that atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP)
are raised in conditions with ventricular volume and pressure overload. In addition to this …

Pulmonary hypertension (PH) is a disease of various origins. Nitric oxide—a potent
vasodilator—is a key player of pulmonary vasoregulation. Nitric oxide signaling is mainly …

The spectrum of scleroderma spans Raynaud's phenomenon, localized forms of skin fibrosis
and the clinically most important forms of systemic sclerosis that involve inflammatory …